C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

abstract：:Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (...

journal_title：Therapeutic advances in neurological disorders

authors： Steinhoff BJ,Staack AM

更新日期：2019-09-09 00:00:00

abstract：:Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

journal_title：Therapeutic advances in neurological disorders

authors： Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

更新日期：2019-09-25 00:00:00

abstract：:Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. However, the role of magnetic resonance imaging (MRI) in MS goes far beyond its clinical application. Indeed, advanced imaging techniques have helped to detect different components of MS patho...

journal_title：Therapeutic advances in neurological disorders

authors： Cortese R,Collorone S,Ciccarelli O,Toosy AT

更新日期：2019-06-27 00:00:00

abstract：:Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

journal_title：Therapeutic advances in neurological disorders

authors： Fernández O

更新日期：2013-03-01 00:00:00

abstract：Background:Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more robustly with clinical disability than traditional, lesion-based metrics. We compare Structural Image Evaluation using Normalisation of Atrophy (SIENA) with the icobrain longitudinal pipeline (icobrain long), for assessment of long...

journal_title：Therapeutic advances in neurological disorders

authors： Beadnall HN,Wang C,Van Hecke W,Ribbens A,Billiet T,Barnett MH

更新日期：2019-01-25 00:00:00

abstract：OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

journal_title：Therapeutic advances in neurological disorders

authors： Hadden RD,Marreno F

更新日期：2015-01-01 00:00:00

abstract：:Neuroinflammation is one of the key components contributing to the devastating outcome of ischemic stroke. Starting with stroke onset, inflammatory processes contribute both to cell damage and tissue remodeling. The early release of alarmins triggers the upregulation of multiple proinflammatory cytokines, resulting in...

journal_title：Therapeutic advances in neurological disorders

authors： Dzyubenko E,Manrique-Castano D,Kleinschnitz C,Faissner A,Hermann DM

更新日期：2018-12-17 00:00:00

abstract：:The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

journal_title：Therapeutic advances in neurological disorders

authors： Tallner A,Pfeifer K,Mäurer M

更新日期：2016-07-01 00:00:00

abstract：:Our inability to identify the invasive margin of glioblastomas hampers attempts to achieve local control. Diffusion tensor imaging (DTI) has been implemented clinically to delineate the margin of the tumor infiltration, its derived anisotropic (q) values can extend beyond the contrast-enhanced area and correlates clos...

journal_title：Therapeutic advances in neurological disorders

authors： Yan JL,Li C,Boonzaier NR,Fountain DM,Larkin TJ,Matys T,van der Hoorn A,Price SJ

更新日期：2019-05-14 00:00:00

abstract：:Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

journal_title：Therapeutic advances in neurological disorders

authors： Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

更新日期：2013-05-01 00:00:00

abstract：:Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

journal_title：Therapeutic advances in neurological disorders

authors： Hellman A,Torres-Russotto D

更新日期：2015-03-01 00:00:00

abstract：:Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

journal_title：Therapeutic advances in neurological disorders

authors： Salama M,Arias-Carrión O

更新日期：2011-11-01 00:00:00

abstract：Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

journal_title：Therapeutic advances in neurological disorders

authors： Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

更新日期：2019-04-24 00:00:00

abstract：:Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

journal_title：Therapeutic advances in neurological disorders

authors： Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

更新日期：2018-10-05 00:00:00

abstract：Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

journal_title：Therapeutic advances in neurological disorders

authors： Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

更新日期：2019-12-02 00:00:00

abstract：:Spinal muscular atrophy (SMA) is a progressive, recessively inherited neuromuscular disease, characterized by the degeneration of lower motor neurons in the spinal cord and brainstem, which leads to weakness and muscle atrophy. SMA currently represents the most common genetic cause of infant death. SMA is caused by th...

journal_title：Therapeutic advances in neurological disorders

authors： Parente V,Corti S

更新日期：2018-02-05 00:00:00

abstract：OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic ...

journal_title：Therapeutic advances in neurological disorders

authors： Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

更新日期：2016-09-01 00:00:00

abstract：:The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

journal_title：Therapeutic advances in neurological disorders

authors： Sorensen PS

更新日期：2008-09-01 00:00:00

abstract：:Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

journal_title：Therapeutic advances in neurological disorders

authors： Haussleiter IS,Brüne M,Juckel G

更新日期：2009-01-01 00:00:00

abstract：:Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

journal_title：Therapeutic advances in neurological disorders

authors： Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

更新日期：2020-06-03 00:00:00

abstract：:Topiramate has been widely utilized worldwide as an effective medication against partial- and generalized-onset seizures. Extended-release topiramate was developed to provide patients with the convenience of once-daily dosing and potentially improved tolerability by reducing serum concentration fluctuation. USL255 is ...

journal_title：Therapeutic advances in neurological disorders

authors： Chung SS

更新日期：2015-05-01 00:00:00

abstract：:Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

journal_title：Therapeutic advances in neurological disorders

authors： Subirós N,Del Barco DG,Coro-Antich RM

更新日期：2012-05-01 00:00:00

abstract：:B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune...

journal_title：Therapeutic advances in neurological disorders

authors： Sorensen PS,Blinkenberg M

更新日期：2016-01-01 00:00:00

abstract：:Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

journal_title：Therapeutic advances in neurological disorders

authors： Haggiag S,Ruggieri S,Gasperini C

更新日期：2013-11-01 00:00:00

abstract：:Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

journal_title：Therapeutic advances in neurological disorders

authors： Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

更新日期：2018-08-09 00:00:00

abstract：:A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive computer-based language therapy program in a group of eight individuals with chronic...

journal_title：Therapeutic advances in neurological disorders

authors： Archibald LM,Orange JB,Jamieson DJ

更新日期：2009-09-01 00:00:00

abstract：:Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since th...

journal_title：Therapeutic advances in neurological disorders

authors： Ramiro L,Simats A,García-Berrocoso T,Montaner J

更新日期：2018-08-06 00:00:00

abstract：:The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early t...

journal_title：Therapeutic advances in neurological disorders

authors： Freedman MS

更新日期：2014-11-01 00:00:00

abstract：:Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily, oral immunomodulatory therapy, has demonstrated efficacy across...

journal_title：Therapeutic advances in neurological disorders

authors： Miller AE

更新日期：2017-12-01 00:00:00

abstract：:More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common thera...

journal_title：Therapeutic advances in neurological disorders

authors： Chung SS

更新日期：2010-03-01 00:00:00